Syracuse, New York – The University of the University has begun injecting humans with the experimental Covid-19 vaccine as part of a large study by Pfizer, which will include 30,000 people in the United States, Brazil, Argentina and Germany.
Upstate is one of 62 participating research centers in the country. He is looking for volunteers to participate in the study to evaluate the safety and effectiveness of a potential vaccine.
Four people received the vaccine in Upstadt this morning, said Dr. Tim Andy, of the Department of Microbiology and Immunology in Upstadt.
There are no approved vaccines to prevent Covid-19, which has been distributed worldwide since the beginning of this year.
Pfizer is developing its potential vaccine with German company BioNTech. There are many other companies preparing to release the vaccine as the United States struggles with a surge in Covid-19 cases.
This week, Modern, a Massachusetts biotechnology company, also began a large-scale clinical trial in the United States of another Covid-19 vaccine.
The federal government has agreed to pay $ 1.95 billion for the purchase of 100 million doses of Pfizer by the end of this year, if research shows that it is safe and effective. The agreement was signed as part of Operation Warp Speed, an effort by the Trump administration to accelerate the development and production of vaccines and treatments to combat the new coronavirus.
Dr Anthony Foachy, a leading federal government expert on infectious diseases, said he was “cautiously optimistic” on Tuesday that a viable Covid-19 vaccine could be available this fall.
Pfizer said its potential vaccine proved to be a strong candidate based on its safety assessments and immune response. The company said in a statement that there were no serious side effects among the 120 people who received the vaccine in the previous study. It said that the side effects of the experimental vaccine were mild to moderate, including fever, fatigue and chills.
Research in Upstate will be randomized. This means that some participants will receive a placebo and others a potential vaccine. Most research groups do not know which people receive a placebo or experimental vaccine.
To be eligible for the study, people must be healthy, between the ages of 18 and 85, and be able to commit to a two-year study. Volunteers will be required to donate blood samples up to two years after receiving the vaccine / placebo. People can see up to ten times during the two-year training period. The two-year study time frame is important for assessing safety and long-term immune response.
Completed individuals declare that they will receive compensation for their participation and will not incur any costs for participation in the study.
Individuals who have previously tested positive for Covid-19 are not eligible. Blood tests can show if the vaccine is eliciting an immune response in participants who may be fighting the virus.
During their first two study visits, participants will receive a research vaccine or a placebo injection. Nasal swabs for Covid-19 testing will also be collected at this time. Blood samples will be taken during other study visits to be submitted.
Participants will be required to keep daily records of any specific reactions for seven days after receiving the placebo / study vaccine.
Those interested in participating in the study can call 315-464-9869 or e-mail firstname.lastname@example.org for more information.
James T. Mulder covers health news. Do you have a news tip? Contact him at (315) 470-2245 or email@example.com